Natixis’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Natixis’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-83,623	Closed	-$6.3M	–	1209
2022 Q2	$6.3M	Buy	+83,623	New	+$3.72M	0.02%	392
2020 Q3	–	Sell	-129,663	Closed	-$8.38M	–	907
2020 Q2	$8.38M	Buy	+129,663	New	+$7.48M	0.07%	214

Natixis's TPTX Position: Q3 2022 in Review

Natixis sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 83,623 shares — an estimated $6.3M sold.

Natixis first reported a position in TPTX in Q2 2020 and held it in 2 quarters. The position peaked at $8.38M in Q2 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Natixis reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Natixis sold 83,623 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $6.3M.
Natixis first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
Natixis's Turning Point Therapeutics, Inc. Common Stock position peaked at $8.38M in Q2 2020.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Natixis's 13F filing for Q3 2022, filed 14 Nov 2022.